Referência de medicamentos
Lorlatinib
Lorlatinib is a medicine in the class oncology. It is used for lung cancer.
- Classe do medicamento: Oncology
- Indicado para: lung cancer
Última atualização
Para profissionais de saúde — apenas referência. Esta página é um resumo breve, não é aconselhamento médico nem substitui a bula oficial ou o julgamento clínico. Verifique sempre antes de prescrever ou dispensar.
O conteúdo clínico desta página está disponível apenas em inglês.
Pontos-chave
- Classe do medicamento
- Oncology
- Código ATC
- L01ED05
- Formas farmacêuticas comuns
- comprimido
- Concentrações comuns
- 25 mg, 100 mg
- Interações conhecidas
- 354 (Contraindicada: 18 · Grave: 101 · Moderada: 209 · Leve: 26)
- Nomes comerciais
- 5
- Países e mercados
- 4
Para que é usado
Como funciona
ALK/ROS1 tyrosine kinase inhibitor, ALK and ROS1 kinases promote tumor progression in ALK/ROS1 positive lung cancer; lorlatinib binds to and inhibits both kinases, which leads to a disruption of the ALK- and ROS1-mediated signaling; this disruption can subsequently inhibit tumor cell growth in ALK- and ROS1-overexpressing tumor cells
Dose habitual em adultos (resumo da bula)
Non-small Cell Lung Cancer: 100 mg PO qDay with or without food, Continue until disease progression or unacceptable toxicity
Gravidez e amamentação
- Gravidez
- Unsafe No available data on use in pregnant women, Based on findings from animal studies and its mechanism of action, embryo-fetal harm may occur when administered to a pregnant woman
- Amamentação
- Unsafe Because of potential for serious adverse reactions in breastfed infants, instruct women not to breastfeed during treatment and for 7 days after final dose
Efeitos adversos relatados
- Hypercholesterolemia
- Edema
- Hyperglycemia
- Anemia
- Peripheral neuropathy
- Increased ALT & AST
Quem deve ter cuidado
- ALT or AST elevations occurred within 3 days and returned to within normal limits after a median of 15 days; median time to recovery for Grade ≥3 was 18 days and for Grade 2 was 7 days
- A broad spectrum of CNS effects may occur, These include seizures, psychotic effects and changes in cognitive function, mood (including suicidal ideation), speech, mental status, and sleep
- Avoid coadministration of Fluconazole may increase lorlatinib plasma concentrations and risk of adverse reactions
Informe ao farmacêutico ou ao médico sobre gravidez ou amamentação, doença renal ou hepática, alergias e todos os outros medicamentos ou suplementos que você usa.
Principais interações (354)
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
- Lonafarnib + Lorlatinib Contraindicated
- Lorlatinib + Lumacaftor / ivacaftor Contraindicated
- Lorlatinib + Mitotane Contraindicated
- Lorlatinib + Pentobarbital Contraindicated
Para assinantes do Pro+
Desbloqueie a página completa
Crie uma conta e comece um teste do Pro+ para abrir a monografia completa de Lorlatinib: doses, gravidez e amamentação, efeitos adversos, advertências e todas as interações.
- Dosing by age, kidney and liver function, and further dose lines
- Paediatric dosing
- Patient counselling points
- Food interactions
Experimente o Pro+ grátis por 14 dias na web. Sem cartão.
Outros medicamentos desta classe
Perguntas frequentes
What is Lorlatinib used for?
Lorlatinib is a medicine in the class oncology. It is used for Lung cancer.
What side effects have been reported with Lorlatinib?
Hypercholesterolemia, Edema, Hyperglycemia, Anemia, Peripheral neuropathy, Increased ALT & AST.
Can Lorlatinib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. No available data on use in pregnant women, Based on findings from animal studies and its mechanism of action, embryo-fetal harm may occur when administered to a pregnant woman Breastfeeding: Unsafe. Because of potential for serious adverse reactions in breastfed infants, instruct women not to breastfeed during treatment and for 7 days after final dose
What does Lorlatinib interact with?
MediHelp lists 354 known interactions for Lorlatinib. Contraindicated: 18 · Major: 101 · Moderate: 209 · Minor: 26. The most serious include Amobarbital, Apalutamide, Butabarbital.
Monografias completas, posologia e verificador de interações no app MediHelp
Abra a referência completa, verifique interações entre vários medicamentos e use as ferramentas de posologia no app MediHelp.
